#ACR23 Abstr#2334 Can we achieve #SLE DORIS remission with current therapy? Post-hoc analyses of 3 x RCTs + LTE over 4 years showed anifrolumab therapy was associated with more frequent and sustained remission vs PBO during the 4-year period. Good for long-term outcomes @RheumNow https://t.co/eq02yChTZr

Rashes in Rheumatology at #ACR23 Name the rash? @Rheumnow https://t.co/uFjXEOHczZ

• https://twitter.com/MeralElRamahiMD/status/1724549534309663000/photo/1

Dysautonomia & joint hypermobility/hEDS - we all know that patients often have both, but what groups of symptoms cluster for patients? This French study showed three main groups - need to look at treatment strategies for each group individually #ACR23 ABST1838 @RheumNow https://t.co/UDepsudpXx

TM83 #ACR23 @RheumNow 45yo M b/l sacroiliitis, Rx MTX -> ADA -> MTX + Tofa. No improv Low Ca, & Phos, ALP 239. Nml Vit D, High PTH. DEXA: Osteoporosis FGF23 high PET/CT showed soft tissue density in nasal septum, few cortical breaks Dx: oncogenic osteomalacia 2/2 malignancy https://t.co/EOcYNtovBy

Review of rashes in SLE at #ACR23 by Dr. Katherine Shaw, MD ⭐️Important to recognize rashes of lupus b/c heterogeneity of cutaneous lupus erythematosus subtypes influences response to treatment. @RheumNow https://t.co/u7dwDe9kbt

Real-world tolerability of anti-fibrotics (nintedanib, pirfenidone) in RA-ILD @BrighamWomens: patients do drop out because of AEs, but a decent chunk are okay and do get modest benefit @Juge_P_A @jeffsparks #ACR23 ABST2479 @RheumNow https://t.co/BpM14eizmF

⭐️Important to recognize rashes of lupus b/c heterogeneity of cutaneous lupus erythematosus subtypes influences response to treatment. 🚩Phase II trial of Iberdomide in SLE: ➡️ not associated w/ statistically significant improvement in CLASI-A when including ALL CLE subtypes… https://t.co/LHNqKMALzU https://t.co/K73sXjFTHM

TM84 #ACR23 @RheumNow 49F MS on RTX, severe arthralgias/wt loss, BMI 18. Spontaneous peritonitis, aseptic discitis/osteo, distal radius lucency, hyperammonemia, hypogammaglobulinemia w 1 yr arthritis Dx: Mycoplasma: ureaplasma urealyticam on culture, PCR improved https://t.co/jM0sARLZS7

RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.

Watch: Correlation Between Patient and Physicians Assessments in PsA Save Dr. Antoni Chan interviews Dr. Avin Maroof at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23 https://t.co/syG4Ry08vF https://t.co/6g9SpISSIt

• Correlation Between Patient and Physicians Assessments in PsA | RheumNow

Merging field moving forward - cardio-rheumatology collaboration imp! Calcium scores in older patients with #RA may be the one take away! Very important to risk predict and mitigate CV events . Ofcourse history taking still remains key! session 14T118 #ACR23 @RheumNow https://t.co/xoldFlA8EW

#ACR23 Late-Breaking Abstr#L13 CAR-T is in CT but not RCT yet. Preliminary results from open label (N=3 #SLE of YTB323 (rapcabtagene autocel CD19 directed with preserved T cell stemness) showed favourable CAR T expansion, B cell depletion, early efficacy & safety @RheumNow https://t.co/UQUOfDbFJe

A#2316 #ACR23 @RheumNow 91 SLE pts w COVID v 182 SLE wo COVID ifn 11 SLE/COVID: serious disease 1 death, 7 severe compl W/in 90d, 15% mild/mod SLE flare 2% severe SLE flare Flare rate 17.6% higher than no COVID ifn 5% p=0.001 High HV ifn (2% v 1%) dsDNA/C3 changes not signif diff https://t.co/dxGJNNWuFy

How do we treat #VEXAS - UBA1 mutation Large multicenter cohort - 110 pts, 99% M Confirms the benefit of JAKi and tocilizumab Others not so much @RheumNow #ACR23 #ACRBest #abstL03 https://t.co/tRjO31IHiD

Speaking of real RA drugs for RA-ILD... large multicenter study finds 4 in 5 patients who received ABA had lung stabilization Nice to see observational data; this would be an amazing opportunity for a pragmatic open label RCT @RheumNow #ACR23 Abstr 2165 https://t.co/LTpfjTVAur